InvestorsHub Logo
Followers 36
Posts 383
Boards Moderated 0
Alias Born 01/24/2017

Re: OFP post# 92708

Wednesday, 02/22/2017 2:54:30 PM

Wednesday, February 22, 2017 2:54:30 PM

Post# of 462939

Thanks, it certainly deserves scrutiny.

However, a word of caution on meta analysis like this, these 20 trials were for patient profiles that were all over the map.

(e.g. 45 years, 55, 75 years, varied baseline MMSE profiles, healthy individuals, mild, moderate, severe AD)

It is worth checking the Anavex methodology but my guess is they chose a sub set of this data which matched their patient profile and proved correlation with their statistical analysis. They likely went through the detail data of those 20 trials to find their SOC.

I'll dig up the meta study in my files but my guess is there may not be enough published about the methodology of either analysis to solve to our liking.

Cheers

Mycroft
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News